Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AT3
- Development stage
- Unknown
- Lead developer
- Serpin Pharma
- Modality
- Peptides
- Administration
- Topical
01
Overview
AT3 is a natural peptide candidate developed by Serpin Pharma, currently in Phase 1 clinical development for cosmetic and skin care applications. The asset is part of Serpin Pharma's broader focus on serine protease inhibitor (serpin)-derived peptides, which are designed to harness the anti-inflammatory and tissue-protective properties of proteins such as alpha-1 antitrypsin and antithrombin III. While the specific molecular target and sequence of AT3 have not been publicly disclosed, it is positioned as a natural peptide for the cosmetics market, likely targeting inflammatory or regenerative pathways in the skin to improve dermatological health.
02
Targets
LRP1 (Prolow-density lipoprotein receptor-related protein 1)
Beyond the preview
Go deeper on AT3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AT3.